{
    "abstract": "Background: This study evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) and the reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine (Tdap) when co-administered in adults aged \u226550 years. Methods: In this open label, multi-center study (NCT02052596), participants were randomized 1:1 to the Co-Administration group (RZV dose 1 and Tdap at Day 0 [D0], RZV dose 2 at Month 2 [M2]) or Control group (Tdap at D0, RZV dose 1 at M2, RZV dose 2 at M4). Co-primary objectives were evaluation of the vaccine response rate (VRR) to RZV in the Co-Administration group, and demonstration of non-inferiority of the humoral responses to RZV and Tdap in the Co-Administration compared to Control group. Reactogenicity and safety of RZV and Tdap were also assessed. Results: VRR to RZV was 97.8% in the Co-Administration group. The non-inferiority criterion was met for the humoral response to RZV and for 4 Tdap antigens, but was not met for the Tdap antigen pertactin. Occurrences of solicited, unsolicited and serious adverse events, and potential immune-mediated diseases were similar between groups. Conclusions: Co-administration of RZV and Tdap did not interfere with the humoral immune response to RZV or 4 of the 5 Tdap antigens. No safety concerns were identified.",
    "author_highlights": [
        {
            "endOffset": 18416,
            "sentence": "RZV immunogenicity was unaffected by co-administration with Tdap.",
            "startOffset": 18351
        },
        {
            "endOffset": 18500,
            "sentence": "Non-inferiority was met for 4 of the 5 Tdap antigens when co-administered with RZV.",
            "startOffset": 18417
        },
        {
            "endOffset": 18575,
            "sentence": "No safety concerns were identified for co-administration of RZV with Tdap.",
            "startOffset": 18501
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Robert H.",
                    "initial": "R.H.",
                    "last": "Dworkin"
                },
                {
                    "first": "Robert W.",
                    "initial": "R.W.",
                    "last": "Johnson"
                },
                {
                    "first": "Judith",
                    "initial": "J.",
                    "last": "Breuer"
                },
                {
                    "first": "John W.",
                    "initial": "J.W.",
                    "last": "Gnann"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Miroslav",
                    "initial": "M.",
                    "last": "Backonja"
                },
                {
                    "first": "Robert F.",
                    "initial": "R.F.",
                    "last": "Betts"
                },
                {
                    "first": "Anne A.",
                    "initial": "A.A.",
                    "last": "Gershon"
                },
                {
                    "first": "Maija L.",
                    "initial": "M.L.",
                    "last": "Haanp\u00e4\u00e4"
                },
                {
                    "first": "Michael W.",
                    "initial": "M.W.",
                    "last": "McKendrick"
                },
                {
                    "first": "Turo J.",
                    "initial": "T.J.",
                    "last": "Nurmikko"
                },
                {
                    "first": "Anne Louise",
                    "initial": "A.L.",
                    "last": "Oaklander"
                },
                {
                    "first": "Michael N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                },
                {
                    "first": "Deborah",
                    "initial": "D.",
                    "last": "Pavan-Langston"
                },
                {
                    "first": "Karin L.",
                    "initial": "K.L.",
                    "last": "Petersen"
                },
                {
                    "first": "Michael C.",
                    "initial": "M.C.",
                    "last": "Rowbotham"
                },
                {
                    "first": "Kenneth E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "Brett R.",
                    "initial": "B.R.",
                    "last": "Stacey"
                },
                {
                    "first": "Stephen K.",
                    "initial": "S.K.",
                    "last": "Tyring"
                },
                {
                    "first": "Albert J.M.",
                    "initial": "A.J.M.",
                    "last": "Van Wijck"
                },
                {
                    "first": "Mark S.",
                    "initial": "M.S.",
                    "last": "Wallace"
                },
                {
                    "first": "Sawko W.",
                    "initial": "S.W.",
                    "last": "Wassilew"
                },
                {
                    "first": "Richard J.",
                    "initial": "R.J.",
                    "last": "Whitley"
                }
            ],
            "doi": "10.1086/510206",
            "firstpage": "S1",
            "issn": "10584838",
            "lastpage": "S26",
            "pmid": "17143845",
            "pub_year": 2007,
            "title": "Recommendations for the management of herpes zoster",
            "volume": "44"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Jeffrey I.",
                    "initial": "J.I.",
                    "last": "Cohen"
                }
            ],
            "doi": "10.1056/NEJMcp1302674",
            "firstpage": "255",
            "issn": "00284793",
            "lastpage": "263",
            "pmid": "23863052",
            "pub_year": 2013,
            "title": "Herpes Zoster",
            "volume": "369"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Robert W.",
                    "initial": "R.W.",
                    "last": "Johnson"
                }
            ],
            "doi": "10.1586/erv.10.30",
            "firstpage": "21",
            "issn": "14760584",
            "lastpage": "26",
            "pmid": "20192714",
            "pub_year": 2010,
            "title": "Herpes zoster and postherpetica neuralgia",
            "volume": "9"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Kosuke",
                    "initial": "K.",
                    "last": "Kawai"
                },
                {
                    "first": "Berhanu G.",
                    "initial": "B.G.",
                    "last": "Gebremeskel"
                },
                {
                    "first": "Camilo J.",
                    "initial": "C.J.",
                    "last": "Acosta"
                }
            ],
            "doi": "10.1136/bmjopen-2014-004833",
            "issn": "20446055",
            "pmid": "24916088",
            "pub_year": 2014,
            "title": "Systematic review of incidence and complications of herpes zoster: Towards a global perspective",
            "volume": "4"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Barbara P.",
                    "initial": "B.P.",
                    "last": "Yawn"
                },
                {
                    "first": "Don",
                    "initial": "D.",
                    "last": "Gilden"
                }
            ],
            "doi": "10.1212/WNL.0b013e3182a3516e",
            "firstpage": "928",
            "issn": "00283878",
            "lastpage": "930",
            "pmid": "23999562",
            "pub_year": 2013,
            "title": "Global perspectives",
            "volume": "81"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Barbara H.",
                    "initial": "B.H.",
                    "last": "Johnson"
                },
                {
                    "first": "Liisa",
                    "initial": "L.",
                    "last": "Palmer"
                },
                {
                    "first": "Justin",
                    "initial": "J.",
                    "last": "Gatwood"
                },
                {
                    "first": "Gregory",
                    "initial": "G.",
                    "last": "Lenhart"
                },
                {
                    "first": "Kosuke",
                    "initial": "K.",
                    "last": "Kawai"
                },
                {
                    "first": "Camilo J.",
                    "initial": "C.J.",
                    "last": "Acosta"
                }
            ],
            "doi": "10.1186/s12879-015-1262-8",
            "issn": "14712334",
            "pmid": "26546419",
            "pub_year": 2015,
            "title": "Annual incidence rates of herpes zoster among an immunocompetent population in the United States",
            "volume": "15"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Anne A.",
                    "initial": "A.A.",
                    "last": "Gershon"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Gershon"
                },
                {
                    "first": "Judith",
                    "initial": "J.",
                    "last": "Breuer"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Anne Louise",
                    "initial": "A.L.",
                    "last": "Oaklander"
                },
                {
                    "first": "Paul D.",
                    "initial": "P.D.",
                    "last": "Griffiths"
                }
            ],
            "doi": "10.1016/S1386-6532(10)70002-0",
            "firstpage": "S2",
            "issn": "13866532",
            "lastpage": "S7",
            "pmid": "20510263",
            "pub_year": 2010,
            "title": "Advances in the understanding of the pathogenesis and epidemiology of herpes zoster",
            "volume": "48"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Harpaz"
                },
                {
                    "first": "Ismael R.",
                    "initial": "I.R.",
                    "last": "Ortega-Sanchez"
                },
                {
                    "first": "Jane F.",
                    "initial": "J.F.",
                    "last": "Seward"
                }
            ],
            "firstpage": "1",
            "issn": "15458601",
            "lastpage": "CE2",
            "pmid": "18528318",
            "pub_year": 2008,
            "title": "Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).",
            "volume": "57"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Adriana",
                    "initial": "A.",
                    "last": "Weinberg"
                },
                {
                    "first": "Jane H.",
                    "initial": "J.H.",
                    "last": "Zhang"
                },
                {
                    "first": "Michael N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                },
                {
                    "first": "Gary R.",
                    "initial": "G.R.",
                    "last": "Johnson"
                },
                {
                    "first": "Anthony R.",
                    "initial": "A.R.",
                    "last": "Hayward"
                },
                {
                    "first": "Michael J.",
                    "initial": "M.J.",
                    "last": "Caulfield"
                },
                {
                    "first": "Michael R.",
                    "initial": "M.R.",
                    "last": "Irwin"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Clair"
                },
                {
                    "first": "Jeffrey G.",
                    "initial": "J.G.",
                    "last": "Smith"
                },
                {
                    "first": "Harold",
                    "initial": "H.",
                    "last": "Stanley"
                },
                {
                    "first": "Rocio D.",
                    "initial": "R.D.",
                    "last": "Marchese"
                },
                {
                    "first": "Ruth",
                    "initial": "R.",
                    "last": "Harbecke"
                },
                {
                    "first": "Heather M.",
                    "initial": "H.M.",
                    "last": "Williams"
                },
                {
                    "first": "Ivan S.F.",
                    "initial": "I.S.F.",
                    "last": "Chan"
                },
                {
                    "first": "Robert D.",
                    "initial": "R.D.",
                    "last": "Arbeit"
                },
                {
                    "first": "Anne A.",
                    "initial": "A.A.",
                    "last": "Gershon"
                },
                {
                    "first": "Florian",
                    "initial": "F.",
                    "last": "Sch\u00f6del"
                },
                {
                    "first": "Vicki A.",
                    "initial": "V.A.",
                    "last": "Morrison"
                },
                {
                    "first": "Carol A.",
                    "initial": "C.A.",
                    "last": "Kauffman"
                },
                {
                    "first": "Steve E.",
                    "initial": "S.E.",
                    "last": "Straus"
                },
                {
                    "first": "Kenneth E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "Larry E.",
                    "initial": "L.E.",
                    "last": "Davis"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                }
            ],
            "doi": "10.1086/605611",
            "firstpage": "1068",
            "issn": "00221899",
            "lastpage": "1077",
            "pmid": "19712037",
            "pub_year": 2009,
            "title": "Varicella-zoster vrrus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine",
            "volume": "200"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Michael N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                }
            ],
            "firstpage": "S13",
            "issn": "00986151",
            "lastpage": "S17",
            "pmid": "19553630",
            "pub_year": 2009,
            "title": "Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence",
            "volume": "109"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Nicolas",
                    "initial": "N.",
                    "last": "Lecrenier"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Beukelaers"
                },
                {
                    "first": "Romulo",
                    "initial": "R.",
                    "last": "Colindres"
                },
                {
                    "first": "Desmond",
                    "initial": "D.",
                    "last": "Curran"
                },
                {
                    "first": "Carine",
                    "initial": "C.",
                    "last": "De Kesel"
                },
                {
                    "first": "Jean Philippe",
                    "initial": "J.P.",
                    "last": "De Saegher"
                },
                {
                    "first": "Arnaud M.",
                    "initial": "A.M.",
                    "last": "Didierlaurent"
                },
                {
                    "first": "Edouard Y.",
                    "initial": "E.Y.",
                    "last": "Ledent"
                },
                {
                    "first": "Johann F.",
                    "initial": "J.F.",
                    "last": "Mols"
                },
                {
                    "first": "Tomas",
                    "initial": "T.",
                    "last": "Mrkvan"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Normand-Bayle"
                },
                {
                    "first": "Lidia",
                    "initial": "L.",
                    "last": "Oostvogels"
                },
                {
                    "first": "Fernanda Tavares",
                    "initial": "F.T.",
                    "last": "Da Silva"
                },
                {
                    "first": "Ventzislav",
                    "initial": "V.",
                    "last": "Vassilev"
                },
                {
                    "first": "Carlota",
                    "initial": "C.",
                    "last": "Vinals"
                },
                {
                    "first": "Alain",
                    "initial": "A.",
                    "last": "Brecx"
                }
            ],
            "doi": "10.1080/14760584.2018.1495565",
            "firstpage": "619",
            "issn": "14760584",
            "lastpage": "634",
            "pmid": "30028651",
            "pub_year": 2018,
            "title": "Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention",
            "volume": "17"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "Anthony L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Diez-Domingo"
                },
                {
                    "first": "Shinn Jang",
                    "initial": "S.J.",
                    "last": "Hwang"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Janet E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "Airi",
                    "initial": "A.",
                    "last": "Poder"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Puig-Barber\u00e0"
                },
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Daisuke",
                    "initial": "D.",
                    "last": "Watanabe"
                },
                {
                    "first": "Lily",
                    "initial": "L.",
                    "last": "Weckx"
                },
                {
                    "first": "Toufik",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1056/NEJMoa1501184",
            "firstpage": "2087",
            "issn": "00284793",
            "lastpage": "2096",
            "pmid": "25916341",
            "pub_year": 2015,
            "title": "Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults",
            "volume": "372"
        },
        "b0065": {
            "authors": [
                {
                    "first": "A. L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Kovac"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "S. J.",
                    "initial": "S.J.",
                    "last": "Hwang"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "D\u00edez-Domingo"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Puig-Barber\u00e0"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Vanden Abeele"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Watanabe"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Ahonen"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Athan"
                },
                {
                    "first": "J. F.",
                    "initial": "J.F.",
                    "last": "Barba-Gomez"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Campora"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "De Looze"
                },
                {
                    "first": "H. J.",
                    "initial": "H.J.",
                    "last": "Downey"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Ghesquiere"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Gorfinkel"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Korhonen"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Leung"
                },
                {
                    "first": "S. A.",
                    "initial": "S.A.",
                    "last": "McNeil"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Oostvogels"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Rombo"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Smetana"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Weckx"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Yeo"
                },
                {
                    "first": "T. C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.1056/NEJMoa1603800",
            "firstpage": "1019",
            "issn": "00284793",
            "lastpage": "1032",
            "pmid": "27626517",
            "pub_year": 2016,
            "title": "Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older",
            "volume": "375"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Anthony L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                },
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Shinn Jang",
                    "initial": "S.J.",
                    "last": "Hwang"
                },
                {
                    "first": "Janet E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Charles",
                    "initial": "C.",
                    "last": "Andrews"
                },
                {
                    "first": "Won Suk",
                    "initial": "W.S.",
                    "last": "Choi"
                },
                {
                    "first": "Meral",
                    "initial": "M.",
                    "last": "Esen"
                },
                {
                    "first": "Hideyuki",
                    "initial": "H.",
                    "last": "Ikematsu"
                },
                {
                    "first": "Martina Kovac",
                    "initial": "M.K.",
                    "last": "Choma"
                },
                {
                    "first": "Karlis",
                    "initial": "K.",
                    "last": "Pauksens"
                },
                {
                    "first": "St\u00e9phanie",
                    "initial": "S.",
                    "last": "Ravault"
                },
                {
                    "first": "Bruno",
                    "initial": "B.",
                    "last": "Salaun"
                },
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Smetana"
                },
                {
                    "first": "Carline Vanden",
                    "initial": "C.V.",
                    "last": "Abeele"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Van den Steen"
                },
                {
                    "first": "Ilse",
                    "initial": "I.",
                    "last": "Vastiau"
                },
                {
                    "first": "Lily Yin",
                    "initial": "L.Y.",
                    "last": "Weckx"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1093/infdis/jiy095",
            "firstpage": "1750",
            "issn": "00221899",
            "lastpage": "1760",
            "pmid": "29529222",
            "pub_year": 2018,
            "title": "Immune responses to a recombinant glycoprotein e herpes zoster vaccine in adults aged 50 years or older",
            "volume": "217"
        },
        "b0075": null,
        "b0080": null,
        "b0085": null,
        "b0090": {
            "authors": [
                {
                    "first": "Kathleen L.",
                    "initial": "K.L.",
                    "last": "Dooling"
                },
                {
                    "first": "Angela",
                    "initial": "A.",
                    "last": "Guo"
                },
                {
                    "first": "Manisha",
                    "initial": "M.",
                    "last": "Patel"
                },
                {
                    "first": "Grace M.",
                    "initial": "G.M.",
                    "last": "Lee"
                },
                {
                    "first": "Kelly",
                    "initial": "K.",
                    "last": "Moore"
                },
                {
                    "first": "Edward A.",
                    "initial": "E.A.",
                    "last": "Belongia"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Harpaz"
                }
            ],
            "doi": "10.15585/mmwr.mm6703a5",
            "firstpage": "103",
            "issn": "01492195",
            "lastpage": "108",
            "pmid": "29370152",
            "pub_year": 2018,
            "title": "Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines",
            "volume": "67"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Sam",
                    "initial": "S.",
                    "last": "Ghebrehewet"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Macpherson"
                },
                {
                    "first": "Antonia",
                    "initial": "A.",
                    "last": "Ho"
                }
            ],
            "doi": "10.1136/bmj.i6258",
            "issn": "09598146",
            "pmid": "27927672",
            "pub_year": 2016,
            "title": "Influenza",
            "volume": "355"
        },
        "b0100": {
            "authors": [
                {
                    "first": "John P.",
                    "initial": "J.P.",
                    "last": "Mullooly"
                },
                {
                    "first": "Carolyn B.",
                    "initial": "C.B.",
                    "last": "Bridges"
                },
                {
                    "first": "William W.",
                    "initial": "W.W.",
                    "last": "Thompson"
                },
                {
                    "first": "Jufu",
                    "initial": "J.",
                    "last": "Chen"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Weintraub"
                },
                {
                    "first": "Lisa A.",
                    "initial": "L.A.",
                    "last": "Jackson"
                },
                {
                    "first": "Steve",
                    "initial": "S.",
                    "last": "Black"
                },
                {
                    "first": "David K.",
                    "initial": "D.K.",
                    "last": "Shay"
                }
            ],
            "doi": "10.1016/j.vaccine.2006.09.041",
            "firstpage": "846",
            "issn": "0264410X",
            "lastpage": "855",
            "pmid": "17074423",
            "pub_year": 2007,
            "title": "Influenza- and RSV-associated hospitalizations among adults",
            "volume": "25"
        },
        "b0105": {
            "authors": [
                {
                    "first": "John E.",
                    "initial": "J.E.",
                    "last": "Stupka"
                },
                {
                    "first": "Eric M.",
                    "initial": "E.M.",
                    "last": "Mortensen"
                },
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Anzueto"
                },
                {
                    "first": "Marcos I.",
                    "initial": "M.I.",
                    "last": "Restrepo"
                }
            ],
            "doi": "10.2217/ahe.09.74",
            "firstpage": "763",
            "issn": "1745509X",
            "lastpage": "774",
            "pub_year": 2009,
            "title": "Community-acquired pneumonia in elderly patients",
            "volume": "5"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Cristina",
                    "initial": "C.",
                    "last": "Masseria"
                },
                {
                    "first": "Girishanthy",
                    "initial": "G.",
                    "last": "Krishnarajah"
                }
            ],
            "doi": "10.1186/s12879-015-1269-1",
            "issn": "14712334",
            "pmid": "26584525",
            "pub_year": 2015,
            "title": "The estimated incidence of pertussis in people aged 50 years old in the United States, 2006-2010",
            "volume": "15"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Catherine Balderston",
                    "initial": "C.B.",
                    "last": "McGuiness"
                },
                {
                    "first": "Jerrold",
                    "initial": "J.",
                    "last": "Hill"
                },
                {
                    "first": "Eileen",
                    "initial": "E.",
                    "last": "Fonseca"
                },
                {
                    "first": "Gregory",
                    "initial": "G.",
                    "last": "Hess"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Hitchcock"
                },
                {
                    "first": "Girishanthy",
                    "initial": "G.",
                    "last": "Krishnarajah"
                }
            ],
            "doi": "10.1186/1471-2334-13-32",
            "issn": "14712334",
            "pmid": "23343438",
            "pub_year": 2013,
            "title": "The disease burden of pertussis in adults 50 years old and older in the United States: A retrospective study",
            "volume": "13"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Geraldine M.",
                    "initial": "G.M.",
                    "last": "McQuillan"
                },
                {
                    "first": "Deanna",
                    "initial": "D.",
                    "last": "Kruszon-Moran"
                },
                {
                    "first": "Adamadia",
                    "initial": "A.",
                    "last": "Deforest"
                },
                {
                    "first": "Susan Y.",
                    "initial": "S.Y.",
                    "last": "Chu"
                },
                {
                    "first": "Melinda",
                    "initial": "M.",
                    "last": "Wharton"
                }
            ],
            "doi": "10.7326/0003-4819-136-9-200205070-00008",
            "firstpage": "660",
            "issn": "00034819",
            "lastpage": "666",
            "pmid": "11992301",
            "pub_year": 2002,
            "title": "Serologic immunity to diphtheria and tetanus in the United States",
            "volume": "136"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Lamont",
                    "initial": "L.",
                    "last": "Sweet"
                },
                {
                    "first": "Darlene",
                    "initial": "D.",
                    "last": "Baxendale"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Neatby"
                },
                {
                    "first": "Petra",
                    "initial": "P.",
                    "last": "Rykers"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Smith"
                },
                {
                    "first": "Mitchell",
                    "initial": "M.",
                    "last": "Zelman"
                },
                {
                    "first": "Diane",
                    "initial": "D.",
                    "last": "Maus"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Lavigne"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Decker"
                }
            ],
            "doi": "10.1097/01.inf.0000202082.56403.c4",
            "firstpage": "195",
            "issn": "08913668",
            "lastpage": "200",
            "pmid": "16511379",
            "pub_year": 2006,
            "title": "How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?",
            "volume": "25"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Hyo Jin",
                    "initial": "H.J.",
                    "last": "Lee"
                },
                {
                    "first": "Jung Hyun",
                    "initial": "J.H.",
                    "last": "Choi"
                }
            ],
            "doi": "10.7774/cevr.2017.6.1.22",
            "firstpage": "22",
            "issn": "22873651",
            "lastpage": "30",
            "pub_year": 2017,
            "title": "Tetanus\u2013diphtheria\u2013acellular pertussis vaccination for adults: An update",
            "volume": "6"
        },
        "b0135": null,
        "b0140": {
            "authors": [
                {
                    "first": "Jennifer L.",
                    "initial": "J.L.",
                    "last": "Liang"
                },
                {
                    "first": "Tejpratap",
                    "initial": "T.",
                    "last": "Tiwari"
                },
                {
                    "first": "Pedro",
                    "initial": "P.",
                    "last": "Moro"
                },
                {
                    "first": "Nancy E.",
                    "initial": "N.E.",
                    "last": "Messonnier"
                },
                {
                    "first": "Arthur",
                    "initial": "A.",
                    "last": "Reingold"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Sawyer"
                },
                {
                    "first": "Thomas A.",
                    "initial": "T.A.",
                    "last": "Clark"
                }
            ],
            "doi": "10.15585/mmwr.rr6702a1",
            "issn": "10575987",
            "pmid": "29702631",
            "pub_year": 2018,
            "title": "Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)",
            "volume": "67"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Naresh",
                    "initial": "N.",
                    "last": "Aggarwal"
                },
                {
                    "first": "Beate",
                    "initial": "B.",
                    "last": "Moeckesch"
                },
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Schenkenberger"
                },
                {
                    "first": "Carine",
                    "initial": "C.",
                    "last": "Claeys"
                },
                {
                    "first": "Martine",
                    "initial": "M.",
                    "last": "Douha"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "Katrijn",
                    "initial": "K.",
                    "last": "Grupping"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                },
                {
                    "first": "Marta Lopez",
                    "initial": "M.L.",
                    "last": "Fauqued"
                },
                {
                    "first": "Lidia",
                    "initial": "L.",
                    "last": "Oostvogels"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Van Den Steen"
                },
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                }
            ],
            "doi": "10.1093/infdis/jix481",
            "firstpage": "1352",
            "issn": "00221899",
            "lastpage": "1361",
            "pmid": "29029224",
            "pub_year": 2017,
            "title": "Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older",
            "volume": "216"
        },
        "b0150": {
            "authors": [
                {
                    "first": "C\u00e9line",
                    "initial": "C.",
                    "last": "Mar\u00e9chal"
                },
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "Airi",
                    "initial": "A.",
                    "last": "Poder"
                },
                {
                    "first": "Murdo",
                    "initial": "M.",
                    "last": "Ferguson"
                },
                {
                    "first": "Igwebuike",
                    "initial": "I.",
                    "last": "Enweonye"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                },
                {
                    "first": "Caroline",
                    "initial": "C.",
                    "last": "Herv\u00e9"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Rheault"
                },
                {
                    "first": "Jaak",
                    "initial": "J.",
                    "last": "Talli"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Wauters"
                },
                {
                    "first": "Lidia",
                    "initial": "L.",
                    "last": "Oostvogels"
                }
            ],
            "doi": "10.1016/j.vaccine.2018.05.110",
            "firstpage": "4278",
            "issn": "0264410X",
            "lastpage": "4286",
            "pmid": "29903674",
            "pub_year": 2018,
            "title": "Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults \u226550\u202fyears of age: A randomized trial",
            "volume": "36"
        },
        "b0155": null,
        "b0160": {
            "authors": [
                {
                    "first": "Robert G.",
                    "initial": "R.G.",
                    "last": "Newcombe"
                }
            ],
            "doi": "10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I",
            "firstpage": "873",
            "issn": "02776715",
            "lastpage": "890",
            "pmid": "9595617",
            "pub_year": 1998,
            "title": "Interval estimation for the difference between independent proportions: Comparison of eleven methods",
            "volume": "17"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Jos\u00e9 M.",
                    "initial": "J.M.",
                    "last": "Bayas"
                },
                {
                    "first": "Harry",
                    "initial": "H.",
                    "last": "Collins"
                },
                {
                    "first": "Maria Luisa Rodriguez",
                    "initial": "M.L.R.",
                    "last": "De La Pinta"
                },
                {
                    "first": "Edouard",
                    "initial": "E.",
                    "last": "Ledent"
                },
                {
                    "first": "Johann F.",
                    "initial": "J.F.",
                    "last": "Mols"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.1093/infdis/jit365",
            "firstpage": "1953",
            "issn": "00221899",
            "lastpage": "1961",
            "pmid": "23904292",
            "pub_year": 2013,
            "title": "Safety and immunogenicity of an ASO1 -adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults \u226550 years of age",
            "volume": "208"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Smetana"
                },
                {
                    "first": "Karlis",
                    "initial": "K.",
                    "last": "Pauksens"
                },
                {
                    "first": "Lars",
                    "initial": "L.",
                    "last": "Rombo"
                },
                {
                    "first": "J. Anneke R.",
                    "initial": "J.A.R.",
                    "last": "Van den Hoek"
                },
                {
                    "first": "Jan H.",
                    "initial": "J.H.",
                    "last": "Richardus"
                },
                {
                    "first": "Georg",
                    "initial": "G.",
                    "last": "Plassmann"
                },
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Edouard",
                    "initial": "E.",
                    "last": "Ledent"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.01.019",
            "firstpage": "1745",
            "issn": "0264410X",
            "lastpage": "1753",
            "pmid": "24508036",
            "pub_year": 2014,
            "title": "Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study",
            "volume": "32"
        },
        "b0175": null,
        "b0180": {
            "authors": [
                {
                    "first": "M. E.",
                    "initial": "M.E.",
                    "last": "Camargo"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Silveira"
                },
                {
                    "first": "J. A.",
                    "initial": "J.A.",
                    "last": "Furuta"
                },
                {
                    "first": "E. P.",
                    "initial": "E.P.",
                    "last": "Oliveira"
                },
                {
                    "first": "O. A.",
                    "initial": "O.A.",
                    "last": "Germek"
                }
            ],
            "doi": "10.1128/jcm.20.4.772-774.1984",
            "firstpage": "772",
            "issn": "00951137",
            "lastpage": "774",
            "pmid": "6386879",
            "pub_year": 1984,
            "title": "Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum",
            "volume": "20"
        },
        "b0185": {
            "authors": [
                {
                    "first": "Moira E.",
                    "initial": "M.E.",
                    "last": "Melville-Smith"
                },
                {
                    "first": "Valerie A.",
                    "initial": "V.A.",
                    "last": "Seagroatt"
                },
                {
                    "first": "Johanna T.",
                    "initial": "J.T.",
                    "last": "Watkins"
                }
            ],
            "doi": "10.1016/S0092-1157(83)80038-9",
            "firstpage": "137",
            "issn": "00921157",
            "lastpage": "144",
            "pmid": "6345548",
            "pub_year": 1983,
            "title": "A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera",
            "volume": "11"
        },
        "b0190": null,
        "b0195": {
            "authors": [
                {
                    "first": "Wayde M.",
                    "initial": "W.M.",
                    "last": "Weston"
                },
                {
                    "first": "Vijayalakshmi",
                    "initial": "V.",
                    "last": "Chandrashekar"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Howe"
                }
            ],
            "doi": "10.4161/hv.9961",
            "issn": "15548600",
            "pmid": "19838080",
            "pub_year": 2009,
            "title": "Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults",
            "volume": "5"
        },
        "b0200": {
            "authors": [
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Leonardi"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Latiolais"
                },
                {
                    "first": "Kwabena",
                    "initial": "K.",
                    "last": "Sarpong"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Simon"
                },
                {
                    "first": "Jerry",
                    "initial": "J.",
                    "last": "Twiggs"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Lei"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Rinderknecht"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Blatter"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Yaela",
                    "initial": "Y.",
                    "last": "Baine"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                },
                {
                    "first": "Carmen",
                    "initial": "C.",
                    "last": "Baccarini"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.09.064",
            "firstpage": "924",
            "issn": "0264410X",
            "lastpage": "932",
            "pmid": "25305567",
            "pub_year": 2015,
            "title": "Immunogenicity and reactogenicity of Infanrix\u2122 when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix\u2122 and Pediarix\u2122",
            "volume": "33"
        },
        "b0205": {
            "authors": [
                {
                    "first": "H. J.",
                    "initial": "H.J.",
                    "last": "Schmitt"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Schuind"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Beutel"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Schulte-Wissermann"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Gahr"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Schult"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Folkens"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Rauh"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Bogaerts"
                },
                {
                    "first": "H. L.",
                    "initial": "H.L.",
                    "last": "Bork"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Clemens"
                }
            ],
            "doi": "10.1016/S0022-3476(96)70152-X",
            "firstpage": "695",
            "issn": "00223476",
            "lastpage": "701",
            "pmid": "8917236",
            "pub_year": 1996,
            "title": "Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants",
            "volume": "129"
        },
        "b0210": {
            "authors": [
                {
                    "first": "Heinz J.",
                    "initial": "H.J.",
                    "last": "Schmitt"
                },
                {
                    "first": "Carl H.Wirsing",
                    "initial": "C.H.W.",
                    "last": "Von K\u00f6nig"
                },
                {
                    "first": "Albrecht",
                    "initial": "A.",
                    "last": "Neiss"
                },
                {
                    "first": "Hugues",
                    "initial": "H.",
                    "last": "Bogaerts"
                },
                {
                    "first": "Hans L.",
                    "initial": "H.L.",
                    "last": "Bock"
                },
                {
                    "first": "Hermann",
                    "initial": "H.",
                    "last": "Schulte-Wissermann"
                },
                {
                    "first": "Manfred",
                    "initial": "M.",
                    "last": "Gahr"
                },
                {
                    "first": "Rainer",
                    "initial": "R.",
                    "last": "Schult"
                },
                {
                    "first": "Jens U.",
                    "initial": "J.U.",
                    "last": "Folkens"
                },
                {
                    "first": "Wolfgang",
                    "initial": "W.",
                    "last": "Rauh"
                },
                {
                    "first": "Ralf",
                    "initial": "R.",
                    "last": "Clemens"
                }
            ],
            "doi": "10.1001/jama.275.1.37",
            "firstpage": "37",
            "issn": "00987484",
            "lastpage": "41",
            "pmid": "8531284",
            "pub_year": 1996,
            "title": "Efficacy of acellular pertussis vaccine in early childhood after household exposure",
            "volume": "275"
        },
        "b0215": {
            "authors": [
                {
                    "first": "Wayde M.",
                    "initial": "W.M.",
                    "last": "Weston"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                },
                {
                    "first": "Xiangfeng",
                    "initial": "X.",
                    "last": "Wu"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Howe"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.11.057",
            "firstpage": "1017",
            "issn": "0264410X",
            "lastpage": "1022",
            "pmid": "21134450",
            "pub_year": 2011,
            "title": "Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration",
            "volume": "29"
        },
        "b0220": null
    },
    "body_text": [
        {
            "endOffset": 26425,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The RZV vaccine (Shingrix, GSK) contains 50 \u03bcg of VZV gE antigen and the GSK proprietary AS01B Adjuvant System (containing 50 \u03bcg MPL [3-O-desacyl-4\u2032-monophosphoryl lipid A; produced by GSK], 50 \u03bcg QS-21 [Quillaja saponaria Molina, fraction 21; licensed by GSK from Antigenics LLC, a wholly owned subsidiary of Agenus Inc., a Delaware, USA corporation] and liposome) per 0.5 mL of reconstituted vaccine.",
            "startOffset": 26023,
            "title": "Study vaccines"
        },
        {
            "endOffset": 41100,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 41099,
                    "startOffset": 41092
                },
                "b0150": {
                    "endOffset": 41099,
                    "startOffset": 41092
                }
            },
            "secId": "s0085",
            "sentence": "These observations are consistent with findings of previous co-administration studies with RZV [29,30].",
            "startOffset": 40997,
            "title": "Discussion"
        },
        {
            "endOffset": 45576,
            "parents": [],
            "secId": "s0105",
            "sentence": "The data reported in this manuscript have not been presented previously.",
            "startOffset": 45504,
            "title": "Previous presentation"
        },
        {
            "endOffset": 30302,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "For anti-FHA, anti-PT and anti-PRN, the fixed-effect model included only treatment as a fixed effect.",
            "startOffset": 30201,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 21345,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 21344,
                    "startOffset": 21338
                },
                "b0040": {
                    "endOffset": 21344,
                    "startOffset": 21338
                },
                "b0045": {
                    "endOffset": 21344,
                    "startOffset": 21338
                },
                "b0050": {
                    "endOffset": 21344,
                    "startOffset": 21338
                }
            },
            "secId": "s0005",
            "sentence": "This increase in HZ risk is thought to be caused by an age-related decline in VZV-specific cellular immunity [7\u201310].",
            "startOffset": 21229,
            "title": "Introduction"
        },
        {
            "endOffset": 42609,
            "parents": [],
            "secId": "s0085",
            "sentence": "Safety outcomes should also be interpreted knowing that the Co-Ad and Control groups did not follow the same study schedule (two versus three vaccination visits, respectively) and Co-Ad participants were followed until M14 while Control participants followed until M16.",
            "startOffset": 42340,
            "title": "Discussion"
        },
        {
            "endOffset": 44059,
            "parents": [],
            "secId": "s0100",
            "sentence": "LC, IE, TCH, HL, NS and AS performed the study.",
            "startOffset": 44012,
            "title": "Author\u2019s contributions"
        },
        {
            "endOffset": 45653,
            "parents": [],
            "secId": "s0110",
            "sentence": "Shingrix and Boostrix are trademarks of the GSK group of companies.",
            "startOffset": 45586,
            "title": "Trademarks"
        },
        {
            "endOffset": 33415,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Seventy-three vaccinated participants were excluded from all analyses as their study center was closed in August 2014.",
            "startOffset": 33297,
            "title": "Study participants"
        },
        {
            "endOffset": 34123,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The mean ages were 63.4 (standard deviation [SD]: 8.4) and 63.1 (SD: 9.0) years in the Co-Ad and Control groups, respectively, and most participants were Caucasian in both study groups.",
            "startOffset": 33938,
            "title": "Study participants"
        },
        {
            "endOffset": 42002,
            "parents": [],
            "secId": "s0085",
            "sentence": "Overcoming barriers to adult immunization, including generating immunogenicity and safety data for vaccine co-administration, is a key component of furthering adult vaccination as a public health strategy.",
            "startOffset": 41797,
            "title": "Discussion"
        },
        {
            "endOffset": 30408,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The pre-vaccination log-transformed concentrations were included as continuous covariates in both models.",
            "startOffset": 30303,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 40707,
            "parents": [],
            "refoffsets": {
                "b0195": {
                    "endOffset": 40706,
                    "startOffset": 40696
                },
                "b0200": {
                    "endOffset": 40706,
                    "startOffset": 40696
                },
                "b0215": {
                    "endOffset": 40706,
                    "startOffset": 40696
                }
            },
            "secId": "s0085",
            "sentence": "The failure to demonstrate immunological non-inferiority for humoral responses to all pertussis antigens has been described in other co-administration settings where the DTaP or Tdap was co-administered with the trivalent influenza vaccine, the tetravalent meningococcal conjugate vaccine, and the quadrivalent meningococcal tetanus toxoid conjugate vaccine [39,40,43].",
            "startOffset": 40338,
            "title": "Discussion"
        },
        {
            "endOffset": 25198,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The secondary objective of this study was to evaluate the safety and reactogenicity of RZV and Tdap when co-administered or administered sequentially.",
            "startOffset": 25048,
            "title": "Study design"
        },
        {
            "endOffset": 25707,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Adults were excluded from participation if they had a history of HZ, or had received any HZ, VZV, or Tdap vaccine at any time before the study or any vaccine against diphtheria or tetanus within the 5 years preceding the study.",
            "startOffset": 25480,
            "title": "Study participants"
        },
        {
            "endOffset": 44636,
            "parents": [],
            "secId": "s0141",
            "sentence": "HL received salary and stock as part of his employee remuneration.",
            "startOffset": 44570,
            "title": "Declaration of Competing Interest"
        },
        {
            "endOffset": 34391,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "One month post-RZV dose 2, VRR to RZV was 97.8% (95% CI: 95.8\u201399.1) in the Co-Ad group; therefore, the success criterion for the VRR objective (LL of the 95% CI \u226560%) was met (Table 2).",
            "startOffset": 34206,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 29132,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "All solicited local reactions were considered causally related to vaccination.",
            "startOffset": 29054,
            "title": "Assessment of reactogenicity and safety"
        },
        {
            "endOffset": 43435,
            "parents": [],
            "secId": "s0090",
            "sentence": "No safety concerns were identified.",
            "startOffset": 43400,
            "title": "Conclusions"
        },
        {
            "endOffset": 39024,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 39023,
                    "startOffset": 39013
                },
                "b0165": {
                    "endOffset": 39023,
                    "startOffset": 39013
                },
                "b0170": {
                    "endOffset": 39023,
                    "startOffset": 39013
                },
                "b0175": {
                    "endOffset": 39023,
                    "startOffset": 39013
                }
            },
            "secId": "s0085",
            "sentence": "Furthermore, in both groups, the immunogenicity of RZV, assessed 1M post-RZV dose 2, was consistent with findings of previous phase II and III trials [14,33\u201335].",
            "startOffset": 38863,
            "title": "Discussion"
        },
        {
            "endOffset": 40886,
            "parents": [],
            "secId": "s0085",
            "sentence": "No safety concerns were identified in this study.",
            "startOffset": 40837,
            "title": "Discussion"
        },
        {
            "endOffset": 26679,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The Tdap vaccine (Boostrix, GSK) contains \u22652 international units (IU) diphtheria toxoid (DT), \u226520 IU tetanus toxoid (TT), \u22658 \u03bcg pertussis toxoid (PT), 8 \u03bcg filamentous hemagglutinin (FHA) and 2.5 \u03bcg pertactin (PRN) per 0.5 mL prefilled monodose syringe.",
            "startOffset": 26426,
            "title": "Study vaccines"
        },
        {
            "endOffset": 24157,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study documents were reviewed and approved by applicable regulatory agencies and ethics committees.",
            "startOffset": 24054,
            "title": "Study design"
        },
        {
            "endOffset": 44156,
            "parents": [],
            "secId": "s0100",
            "sentence": "PB, LC, IE, TCH, HL, LO, AES and AS were involved in the analysis or interpretation of the data.",
            "startOffset": 44060,
            "title": "Author\u2019s contributions"
        },
        {
            "endOffset": 45095,
            "parents": [],
            "secId": "s0141",
            "sentence": "LO is employee of CureVacAG as of March 1st 2018.",
            "startOffset": 45046,
            "title": "Declaration of Competing Interest"
        },
        {
            "endOffset": 44939,
            "parents": [],
            "secId": "s0141",
            "sentence": "TCH was a paid consultant for the GSK group of companies during the development of this manuscript.",
            "startOffset": 44840,
            "title": "Declaration of Competing Interest"
        },
        {
            "endOffset": 32823,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0055",
            "sentence": "Reactogenicity and safety of both study vaccines were assessed using descriptive statistics.",
            "startOffset": 32731,
            "title": "Secondary objective"
        },
        {
            "endOffset": 38357,
            "parents": [],
            "secId": "s0085",
            "sentence": "Co-administration of RZV and Tdap induced strong immune responses to the 6 antigens evaluated.",
            "startOffset": 38263,
            "title": "Discussion"
        },
        {
            "endOffset": 37008,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Of these, 27 Co-Ad group and 31 Control group participants reported unsolicited AEs assessed by the investigator to be causally related to vaccination (Table 4).",
            "startOffset": 36847,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 24611,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Anonymized individual participant data and study documents can be requested for further research at www.clinicalstudydatarequest.com.",
            "startOffset": 24478,
            "title": "Study design"
        },
        {
            "endOffset": 22580,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 22579,
                    "startOffset": 22572
                },
                "b0135": {
                    "endOffset": 22579,
                    "startOffset": 22572
                }
            },
            "secId": "s0005",
            "sentence": "Vaccination of adults is important to prevent outbreaks of these vaccine-preventable diseases and to help prevent pertussis transmission to infants younger than 12 months of age [26,27].",
            "startOffset": 22394,
            "title": "Introduction"
        },
        {
            "endOffset": 20886,
            "parents": [],
            "secId": "s0005",
            "sentence": "Primary infection with varicella-zoster virus (VZV) causes chickenpox; thereafter VZV establishes latency in sensory ganglia.",
            "startOffset": 20761,
            "title": "Introduction"
        },
        {
            "endOffset": 36314,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "The median duration of solicited local symptoms reported per dose was 3 days or less.",
            "startOffset": 36229,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 37203,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "These included one grade 3 injection site pruritus and one grade 3 syncope in the Co-Ad group, and one grade 3 viral upper respiratory tract infection and one grade 3 cough in the Control group.",
            "startOffset": 37009,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 21228,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 21227,
                    "startOffset": 21222
                },
                "b0030": {
                    "endOffset": 21227,
                    "startOffset": 21222
                }
            },
            "secId": "s0005",
            "sentence": "The risk of HZ increases with age, with more than 60% of all HZ cases occurring after 50 years of age (YOA) [5,6].",
            "startOffset": 21114,
            "title": "Introduction"
        },
        {
            "endOffset": 32232,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0050",
            "sentence": "The second co-primary objective was demonstrated if, 1M post-RZV dose 2, the upper limit (UL) of the 2-sided 95% CI of the adjusted geometric mean concentration (GMC) ratio (Control over Co-Ad) was <1.5.",
            "startOffset": 32029,
            "title": "Co-primary objectives"
        },
        {
            "endOffset": 44745,
            "parents": [],
            "secId": "s0141",
            "sentence": "TCH continues to own stock and stock options, and LO continues to own stock from the GSK group of companies.",
            "startOffset": 44637,
            "title": "Declaration of Competing Interest"
        },
        {
            "endOffset": 33846,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Of the 830 vaccinated participants, 771 (377 Co-Ad, 394 Control) were included in the ATP cohort for immunogenicity and 768 (385 Co-Ad, 383 Control) of the 830 vaccinated participants completed the study up to the last contact for safety (M14 in Co-Ad, M16 in Control) (Fig. 1).",
            "startOffset": 33568,
            "title": "Study participants"
        },
        {
            "endOffset": 36692,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "The median duration of solicited general symptoms reported per dose was 2 days or less.",
            "startOffset": 36605,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 27166,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0035",
            "sentence": "Humoral immune responses to the study vaccines were assessed from blood samples (\u223c8 mL) collected from participants in the Co-Ad group at D0 (pre-vaccination for RZV and Tdap), M1 (1M post-Tdap vaccination), and M3 (1M post-RZV dose 2); and in the Control group at D0 (pre-Tdap vaccination), M1 (1M post-Tdap vaccination), M2 (pre-RZV vaccination), and M5 (1M post-RZV dose 2).",
            "startOffset": 26789,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 35287,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The anti-PRN GMC increased more than 12-fold over pre-vaccination in the Co-Ad group, and post-vaccination anti-PRN seropositivity rates were similar between the Co-Ad and Control groups 1M post-Tdap vaccination (Table 3).",
            "startOffset": 35065,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 36064,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "The most common solicited local symptom after vaccination was pain, reported after RZV by 83.3% (8.4% grade 3) and 85.4% (9.2% grade 3) of participants in the Co-Ad and Control groups, respectively (Fig. 2A).",
            "startOffset": 35856,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 27326,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0035",
            "sentence": "Anti-gE antibody concentrations were measured using an anti-gE enzyme-linked immunosorbent assay (ELISA) with a seropositivity cut-off of 97 milli IU (mIU)/mL.",
            "startOffset": 27167,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 40338,
            "parents": [],
            "secId": "s0085",
            "sentence": "Taken together, these data do not suggest a clinically relevant interference between RZV and Tdap.",
            "startOffset": 40240,
            "title": "Discussion"
        },
        {
            "endOffset": 42169,
            "parents": [],
            "secId": "s0085",
            "sentence": "The open label design of the study might have introduced bias in the assessment of safety.",
            "startOffset": 42079,
            "title": "Discussion"
        },
        {
            "endOffset": 39591,
            "parents": [],
            "secId": "s0085",
            "sentence": "In addition, one month post-Tdap vaccination, 73.8% and 96.5% participants from the Co-Ad group had anti-D and anti-T antibody concentrations \u22651.0 IU/mL (i.e., \u226510-fold the protective threshold), respectively.",
            "startOffset": 39382,
            "title": "Discussion"
        },
        {
            "endOffset": 33567,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "To maintain the statistical power, 76 additional participants were subsequently enrolled in this study, who were counted in the total of 904 enrollees.",
            "startOffset": 33416,
            "title": "Study participants"
        },
        {
            "endOffset": 40996,
            "parents": [],
            "secId": "s0085",
            "sentence": "Safety and reactogenicity profiles were similar when RZV and Tdap were co-administered or given sequentially.",
            "startOffset": 40887,
            "title": "Discussion"
        },
        {
            "endOffset": 30973,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Missing data or non-evaluable measurements were treated as missing completely at random processes.",
            "startOffset": 30875,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 43954,
            "parents": [],
            "secId": "s0100",
            "sentence": "TCH and HL conceived and designed the study.",
            "startOffset": 43910,
            "title": "Author\u2019s contributions"
        },
        {
            "endOffset": 33937,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "In the TVC, demographic characteristics were well-balanced between study groups (Table 1).",
            "startOffset": 33847,
            "title": "Study participants"
        },
        {
            "endOffset": 37879,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "No pIMDs were reported from first vaccination until study end.",
            "startOffset": 37817,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 38675,
            "parents": [],
            "secId": "s0085",
            "sentence": "Per protocol, co-administration would have been considered non-inferior only if all co-primary objectives were met.",
            "startOffset": 38560,
            "title": "Discussion"
        },
        {
            "endOffset": 25479,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Adults were eligible for participation in the study if they were \u226550 YOA at the time of first vaccination, provided written informed consent before study start, and, in the opinion of the investigator, were able to comply with the requirements of the protocol.",
            "startOffset": 25219,
            "title": "Study participants"
        },
        {
            "endOffset": 26729,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Tdap antigens are adjuvanted with aluminum salts.",
            "startOffset": 26680,
            "title": "Study vaccines"
        },
        {
            "endOffset": 43631,
            "parents": [],
            "secId": "s0090",
            "sentence": "The data from this study show that adults aged \u226550 years may receive RZV and Tdap concomitantly at the same visit and may support the advancement of adult vaccination as a public health strategy.",
            "startOffset": 43436,
            "title": "Conclusions"
        },
        {
            "endOffset": 45312,
            "parents": [],
            "secId": "s0141",
            "sentence": "LC receives shares and AS and AES own stock options as part of their employee remuneration.",
            "startOffset": 45221,
            "title": "Declaration of Competing Interest"
        },
        {
            "endOffset": 45483,
            "parents": [],
            "secId": "s0141",
            "sentence": "NS reports grants from the GSK group of companies during the conduct of the study, and grants from Pfizer, Sanofi Pasteur and Novavax for work outside the submitted work.",
            "startOffset": 45313,
            "title": "Declaration of Competing Interest"
        },
        {
            "endOffset": 24054,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Participants in the Control group received Tdap at D0, the first dose of RZV at M2 and the second dose of RZV at M4.",
            "startOffset": 23938,
            "title": "Study design"
        },
        {
            "endOffset": 22171,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 22170,
                    "startOffset": 22163
                },
                "b0100": {
                    "endOffset": 22170,
                    "startOffset": 22163
                },
                "b0105": {
                    "endOffset": 22170,
                    "startOffset": 22163
                },
                "b0110": {
                    "endOffset": 22170,
                    "startOffset": 22163
                },
                "b0115": {
                    "endOffset": 22170,
                    "startOffset": 22163
                },
                "b0120": {
                    "endOffset": 22170,
                    "startOffset": 22163
                }
            },
            "secId": "s0005",
            "sentence": "Older adults are also at increased risk for other infections and their complications, such as influenza, pneumococcal disease, pertussis, diphtheria and tetanus [19\u201324].",
            "startOffset": 22002,
            "title": "Introduction"
        },
        {
            "endOffset": 42339,
            "parents": [],
            "secId": "s0085",
            "sentence": "As injection site reactions in the dominant arm may interfere more with daily activities, the relative reactogenicity of the vaccines should be interpreted with caution.",
            "startOffset": 42170,
            "title": "Discussion"
        },
        {
            "endOffset": 32029,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0050",
            "sentence": "The first co-primary objective was met if the lower limit (LL) of the 2-sided 95% CI of the VRR for anti-gE antibody concentrations in the Co-Ad group was \u226560%.",
            "startOffset": 31869,
            "title": "Co-primary objectives"
        },
        {
            "endOffset": 23770,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Participants were randomized 1:1 to one of two parallel study arms using a central randomization system on the internet (SBIR, GSK).",
            "startOffset": 23638,
            "title": "Study design"
        },
        {
            "endOffset": 27744,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0035",
            "sentence": "VRR was defined as the percentage of participants who had at least: (i) a 4-fold increase in the post-RZV dose 2 anti-gE antibody concentration compared to the anti-gE cut-off for participants who were seronegative at baseline, or (ii) a 4-fold increase in the post-RZV dose 2 anti-gE antibody concentration compared to the pre-RZV vaccination anti-gE concentration for participants who were seropositive at baseline.",
            "startOffset": 27327,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 31843,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "All statistical analyses were performed using the Statistical Analysis Systems Drug Development Version 4.3.3.",
            "startOffset": 31733,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 37816,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "During the study, 4 deaths occurred in each of the study groups, none of which were considered related to vaccination.",
            "startOffset": 37698,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 35688,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The non-inferiority criterion (UL of 95% CI <10%) for the humoral immune response to Tdap in the Co-Ad versus the Control group was met for anti-D and anti-T (Table 2).",
            "startOffset": 35520,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 41378,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 41377,
                    "startOffset": 41364
                },
                "b0065": {
                    "endOffset": 41377,
                    "startOffset": 41364
                },
                "b0165": {
                    "endOffset": 41377,
                    "startOffset": 41364
                },
                "b0170": {
                    "endOffset": 41377,
                    "startOffset": 41364
                }
            },
            "secId": "s0085",
            "sentence": "Safety and reactogenicity of RZV were generally consistent with the results from previous phase II and III studies [12,13,33,34].",
            "startOffset": 41249,
            "title": "Discussion"
        },
        {
            "endOffset": 30200,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The fixed-effect model for anti-gE included the treatment and age strata as fixed effects.",
            "startOffset": 30110,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 22714,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 22713,
                    "startOffset": 22709
                }
            },
            "secId": "s0005",
            "sentence": "For these reasons, vaccination against diphtheria, tetanus, and pertussis is currently recommended for adults in many countries [26].",
            "startOffset": 22581,
            "title": "Introduction"
        },
        {
            "endOffset": 40039,
            "parents": [],
            "refoffsets": {
                "b0190": {
                    "endOffset": 39670,
                    "startOffset": 39666
                },
                "b0195": {
                    "endOffset": 39841,
                    "startOffset": 39834
                },
                "b0200": {
                    "endOffset": 39841,
                    "startOffset": 39834
                },
                "b0205": {
                    "endOffset": 39973,
                    "startOffset": 39969
                },
                "b0210": {
                    "endOffset": 40038,
                    "startOffset": 40034
                }
            },
            "secId": "s0085",
            "sentence": "Although there is no unequivocal correlate of protection against pertussis [38], efficacy of pertussis antigen-containing vaccines such as Tdap or the diphtheria-tetanus-acellular pertussis vaccine (DTaP) has been inferred in previous studies [39,40] by bridging immune responses for the pertussis antigens PT, FHA, and PRN to those reported in a German Household Contact Study [41], in which DTaP demonstrated >88% efficacy against pertussis [42].",
            "startOffset": 39591,
            "title": "Discussion"
        },
        {
            "endOffset": 43097,
            "parents": [],
            "secId": "s0090",
            "sentence": "In a clinical trial where the first dose of RZV was given concomitantly with Tdap compared to when both vaccines were administered sequentially, immunogenicity non-inferiority criteria were met for all vaccine antigens with the exception of the humoral response to the pertussis antigen, PRN.",
            "startOffset": 42805,
            "title": "Conclusions"
        },
        {
            "endOffset": 29219,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "Causal relationship to vaccination of all other AEs was assessed by the investigators.",
            "startOffset": 29133,
            "title": "Assessment of reactogenicity and safety"
        },
        {
            "endOffset": 30563,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Geometric means (GMs) of post-vaccination concentrations were calculated conditionally to the means of the pre-vaccination log-transformed concentrations.",
            "startOffset": 30409,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 31477,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The analysis of immunogenicity was performed on the according-to-protocol (ATP) cohort for immunogenicity which included participants who met all eligibility criteria, complied with the study procedures and intervals allowed for the analysis, and for whom data concerning immunogenicity endpoint measures were available.",
            "startOffset": 31157,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 21007,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 21006,
                    "startOffset": 21001
                },
                "b0010": {
                    "endOffset": 21006,
                    "startOffset": 21001
                },
                "b0015": {
                    "endOffset": 21006,
                    "startOffset": 21001
                }
            },
            "secId": "s0005",
            "sentence": "Reactivation of latent VZV results in herpes zoster (HZ), which typically manifests as a painful, dermatomal rash [1\u20133].",
            "startOffset": 20887,
            "title": "Introduction"
        },
        {
            "endOffset": 23637,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This phase III, open-label, randomized, multi-center study was conducted at 13 study centers in the US between February 2014 and April 2016.",
            "startOffset": 23497,
            "title": "Study design"
        },
        {
            "endOffset": 29634,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "HZ and/or HZ complications constituted an AE or SAE, as appropriate.",
            "startOffset": 29566,
            "title": "Assessment of reactogenicity and safety"
        },
        {
            "endOffset": 24477,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Full clinical study documents including protocol and clinical study report are available at http://www.gsk-clinicalstudyregister.com (study 116887).",
            "startOffset": 24329,
            "title": "Study design"
        },
        {
            "endOffset": 26022,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Both vaccines were administered intramuscularly in the deltoid muscle of the upper arm (non-dominant arm for RZV, dominant arm for Tdap).",
            "startOffset": 25885,
            "title": "Study vaccines"
        },
        {
            "endOffset": 33296,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Of these, 830 (412 Co-Ad, 418 Control) were included in the TVC.",
            "startOffset": 33232,
            "title": "Study participants"
        },
        {
            "endOffset": 25791,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Persons on chronic immunosuppressive therapy were also excluded from participation.",
            "startOffset": 25708,
            "title": "Study participants"
        },
        {
            "endOffset": 36397,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Overall, the most common solicited general symptom was myalgia followed by fatigue.",
            "startOffset": 36314,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 31157,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "No adjustment was made for the type I error due to multiplicity as the null hypotheses must simultaneously show a significant beneficial effect for the study main objective to be met.",
            "startOffset": 30974,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 41248,
            "parents": [],
            "secId": "s0085",
            "sentence": "The slightly higher number of participants reporting SAEs in the Control group may reflect the longer follow-up period imposed by the study design.",
            "startOffset": 41101,
            "title": "Discussion"
        },
        {
            "endOffset": 27968,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0035",
            "sentence": "Antibodies against DT (anti-D), TT (anti-T) and the three pertussis antigens (anti-PT, anti-FHA and anti-PRN) were measured by ELISA, with seropositivity cut-offs of 0.057, 0.043, 2.693, 2.046, and 2.187 IU/mL, respectively.",
            "startOffset": 27744,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 37603,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "During the entire study period, SAEs were reported by 21 (5.1%) and 31 (7.4%) participants in the Co-Ad and Control groups, respectively (Table 4).",
            "startOffset": 37456,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 23937,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Participants in the Co-Administration (Co-Ad) group received the first dose of RZV and Tdap co-administered at Day 0 (D0), and the second dose of RZV at Month 2 (M2).",
            "startOffset": 23771,
            "title": "Study design"
        },
        {
            "endOffset": 36604,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Myalgia was reported by 55.8% (6.6% grade 3) and 59.0% (7.8% grade 3), while fatigue by 45.7% (7.4% grade 3) and 46.6% (6.6% grade 3) of participants in the Co-Ad and Control groups, respectively (Fig. 2C).",
            "startOffset": 36398,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 21611,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 21499,
                    "startOffset": 21495
                },
                "b0060": {
                    "endOffset": 21610,
                    "startOffset": 21603
                },
                "b0065": {
                    "endOffset": 21610,
                    "startOffset": 21603
                }
            },
            "secId": "s0005",
            "sentence": "An adjuvanted recombinant zoster vaccine containing the VZV glycoprotein E (gE) and the AS01B Adjuvant System (Shingrix, referred to as RZV hereafter [11]) demonstrated 97.2% and 91.3% overall efficacy against HZ in adults aged \u226550 and \u226570 YOA, respectively [12,13].",
            "startOffset": 21345,
            "title": "Introduction"
        },
        {
            "endOffset": 39142,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 39141,
                    "startOffset": 39134
                },
                "b0150": {
                    "endOffset": 39141,
                    "startOffset": 39134
                }
            },
            "secId": "s0085",
            "sentence": "In line with our findings, immunogenicity of RZV was not affected by the co-administration of other vaccines [29,30].",
            "startOffset": 39025,
            "title": "Discussion"
        },
        {
            "endOffset": 25047,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Co-primary objectives of the study were (1) to evaluate the vaccine response rate (VRR) to RZV (based on humoral immune response) in the Co-Ad group 1M post-RZV dose 2; (2) to demonstrate non-inferiority of the humoral immune response to two doses of RZV in the Co-Ad versus Control group 1M post-RZV dose 2; and (3) to demonstrate non-inferiority of humoral responses to Tdap in the Co-Ad versus Control group 1M post-Tdap vaccination.",
            "startOffset": 24611,
            "title": "Study design"
        },
        {
            "endOffset": 34189,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The gender distribution was similar between the two study groups.",
            "startOffset": 34124,
            "title": "Study participants"
        },
        {
            "endOffset": 25868,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Detailed inclusion/exclusion criteria are presented in Supplementary Text 1.",
            "startOffset": 25792,
            "title": "Study participants"
        },
        {
            "endOffset": 39277,
            "parents": [],
            "refoffsets": {
                "b0180": {
                    "endOffset": 39276,
                    "startOffset": 39269
                },
                "b0185": {
                    "endOffset": 39276,
                    "startOffset": 39269
                }
            },
            "secId": "s0085",
            "sentence": "For anti-D and anti-T, an antibody concentration of 0.1 IU/mL (ELISA) provides a conservative estimate of protective threshold [36,37].",
            "startOffset": 39142,
            "title": "Discussion"
        },
        {
            "endOffset": 43744,
            "parents": [],
            "secId": "s0095",
            "sentence": "This work was supported by GlaxoSmithKline Biologicals SA in all stages of the study conduct and analysis.",
            "startOffset": 43638,
            "title": "Funding"
        },
        {
            "endOffset": 35519,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The difference in percentage of participants (Control minus Co-Ad) with antibody concentrations \u22651.0 IU/mL 1M post-Tdap vaccination were 1.52% (95% CI: \u22124.66\u20137.72) and \u22120.84% (95% CI: \u22123.73\u20132.02) for anti-D and anti-T, respectively.",
            "startOffset": 35287,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 40837,
            "parents": [],
            "secId": "s0085",
            "sentence": "Immune interference from co-administration remains one potential etiology for the failure to demonstrate non-inferiority for PRN.",
            "startOffset": 40708,
            "title": "Discussion"
        },
        {
            "endOffset": 22002,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 22001,
                    "startOffset": 21997
                }
            },
            "secId": "s0005",
            "sentence": "In the US, RZV is recommended for the prevention of HZ and related complications for immunocompetent adults \u226550 YOA, including those who previously received the live zoster vaccine [18].",
            "startOffset": 21816,
            "title": "Introduction"
        },
        {
            "endOffset": 38559,
            "parents": [],
            "secId": "s0085",
            "sentence": "While non-inferiority criteria were met for the humoral response to RZV and for 4 Tdap antigens, immunological non-inferiority was not demonstrated for the immune response to the pertussis antigen PRN.",
            "startOffset": 38358,
            "title": "Discussion"
        },
        {
            "endOffset": 29053,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "Unsolicited AEs were graded by the investigators on a scale from 1 (mild: causing minimal discomfort and not interfering with everyday activities) to 3 (severe: preventing normal everyday activities).",
            "startOffset": 28853,
            "title": "Assessment of reactogenicity and safety"
        },
        {
            "endOffset": 45220,
            "parents": [],
            "secId": "s0141",
            "sentence": "LC, PB, IE, AES and AS are employed by the GSK group of companies and receive salary as part of their employee remuneration.",
            "startOffset": 45096,
            "title": "Declaration of Competing Interest"
        },
        {
            "endOffset": 28115,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "Diary cards were provided to the participants to record solicited and unsolicited adverse events (AEs).",
            "startOffset": 28012,
            "title": "Assessment of reactogenicity and safety"
        },
        {
            "endOffset": 44569,
            "parents": [],
            "secId": "s0141",
            "sentence": "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: TCH, LO, and HL were employed by the GSK group of companies at the time this study was conceived, designed, initiated, and/or conducted.",
            "startOffset": 44298,
            "title": "Declaration of Competing Interest"
        },
        {
            "endOffset": 30109,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "An Analysis of Covariance model was used to analyze post-vaccination log-transformed concentrations of anti-gE, anti-FHA, anti-PT and anti-PRN antibodies.",
            "startOffset": 29955,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 42793,
            "parents": [],
            "secId": "s0085",
            "sentence": "A plain language graphical summary contextualizing the results and potential clinical research relevance and impact is displayed in the Focus on Patient Section (Supplementary Fig. 1).",
            "startOffset": 42609,
            "title": "Discussion"
        },
        {
            "endOffset": 41796,
            "parents": [],
            "secId": "s0085",
            "sentence": "As older adults might face barriers to immunization, such as the burden of visits to a healthcare professional for the sole purpose of a vaccination and the lack of awareness of the importance of vaccination in this population segment, the opportunity for co-administration of these two vaccines at the same visit may lead to increased compliance with RZV and Tdap vaccination recommendations in adults aged \u226550 years.",
            "startOffset": 41378,
            "title": "Discussion"
        },
        {
            "endOffset": 38262,
            "parents": [],
            "secId": "s0085",
            "sentence": "This study evaluated the humoral immunogenicity and safety of RZV and Tdap vaccines when they were administered concurrently or sequentially.",
            "startOffset": 38121,
            "title": "Discussion"
        },
        {
            "endOffset": 38862,
            "parents": [],
            "secId": "s0085",
            "sentence": "The VRR to RZV in the Co-Ad group was 97.8% (97.9% in the Control group), and the anti-gE responses to two doses of RZV were similar in the Co-Ad and Control groups at 1M post-RZV dose 2.",
            "startOffset": 38675,
            "title": "Discussion"
        },
        {
            "endOffset": 24328,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice and is registered on ClinicalTrials.gov (NCT02052596).",
            "startOffset": 24158,
            "title": "Study design"
        },
        {
            "endOffset": 21815,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 21814,
                    "startOffset": 21807
                },
                "b0080": {
                    "endOffset": 21814,
                    "startOffset": 21807
                },
                "b0085": {
                    "endOffset": 21814,
                    "startOffset": 21807
                }
            },
            "secId": "s0005",
            "sentence": "RZV is currently approved in several countries worldwide for prevention of HZ in adults aged \u226550 YOA [15\u201317].",
            "startOffset": 21706,
            "title": "Introduction"
        },
        {
            "endOffset": 30735,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The 2-sided 95% CIs for the mean of log-transformed concentrations were first obtained assuming that log-transformed values were normally distributed with unknown variance.",
            "startOffset": 30563,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 29955,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0155": {
                    "endOffset": 29812,
                    "startOffset": 29808
                },
                "b0160": {
                    "endOffset": 29954,
                    "startOffset": 29950
                }
            },
            "secId": "s0045",
            "sentence": "For binomial outcomes, the exact 2-sided 95% confidence intervals (CIs) for proportions within groups were calculated using the Clopper-Pearson method [31], while the 2-sided standardized asymptotic 95% CIs for the between group differences were calculated using Miettinen and Nurminen method [32].",
            "startOffset": 29657,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 34667,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The adjusted GMC ratio (Control over Co-Ad) for anti-gE antibodies 1M post-RZV dose 2 was 1.11 (95% CI: 1.02\u20131.21); therefore, the non-inferiority criterion (UL of the 95% CI <1.5) for the humoral immune response to RZV in the Co-Ad versus the Control group was met (Table 2).",
            "startOffset": 34391,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 35064,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The adjusted GMC ratios (Control over Co-Ad) for anti-FHA, anti-PT, and anti-PRN antibodies 1M post-Tdap vaccination were 1.24 (95% CI: 1.07\u20131.44), 1.17 (95% CI: 1.00\u20131.36), and 1.27 (95% CI: 1.02\u20131.58), respectively.",
            "startOffset": 34847,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 37697,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "No SAEs were assessed by the investigator to have a causal relationship to study vaccination.",
            "startOffset": 37604,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 22393,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 22392,
                    "startOffset": 22388
                }
            },
            "secId": "s0005",
            "sentence": "Adult formulations of vaccines containing tetanus and diphtheria toxoids and acellular pertussis antigens (Tdap) have been developed to prevent pertussis and to re-establish protection against diphtheria and tetanus [25].",
            "startOffset": 22172,
            "title": "Introduction"
        },
        {
            "endOffset": 37995,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "One suspected HZ case was reported for a participant in the Co-Ad group 256 days after administration of RZV dose 2.",
            "startOffset": 37879,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 22865,
            "parents": [],
            "refoffsets": {
                "b0140": {
                    "endOffset": 22864,
                    "startOffset": 22860
                }
            },
            "secId": "s0005",
            "sentence": "In the US, the Centers for Disease Control and Prevention recommend a single dose of Tdap for adults \u226519 YOA previously not vaccinated with Tdap [28].",
            "startOffset": 22715,
            "title": "Introduction"
        },
        {
            "endOffset": 30875,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The 2-sided 95% CIs for the GMs were then obtained by exponential transformation of the CIs for the mean of log-transformed concentrations.",
            "startOffset": 30736,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 29428,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "Serious AEs (SAEs) and potential immune-mediated diseases (pIMDs) were recorded from administration of the first study vaccine dose until the end of the study (approximately 12M post-RZV dose 2 in each group).",
            "startOffset": 29219,
            "title": "Assessment of reactogenicity and safety"
        },
        {
            "endOffset": 36846,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Within 30 days after vaccination, unsolicited AEs were reported by 105 (25.5%) and 118 (28.2%) participants in the Co-Ad and Control groups, respectively.",
            "startOffset": 36692,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 21705,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 21704,
                    "startOffset": 21700
                }
            },
            "secId": "s0005",
            "sentence": "Furthermore, RZV induced robust humoral and cellular immune responses in all age groups [14].",
            "startOffset": 21612,
            "title": "Introduction"
        },
        {
            "endOffset": 44265,
            "parents": [],
            "secId": "s0100",
            "sentence": "All authors contributed to the writing/reviewing of the paper and approved the final version for submission.",
            "startOffset": 44157,
            "title": "Author\u2019s contributions"
        },
        {
            "endOffset": 32707,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0050",
            "sentence": "The third co-primary objective, non-inferiority of the humoral immune response to Tdap in the Co-Ad compared to the Control group, was demonstrated if, 1M post-Tdap vaccination, the UL of the 2-sided 95% CI of the adjusted GMC ratio (Control over Co-Ad) was <1.5 for anti-FHA, anti-PT, and anti-PRN; and the UL of the 2-sided 95% CI for the difference in percentage of participants (Control minus Co-Ad) with antibody concentrations \u22651.0 IU/mL for anti-D and anti-T was <10%.",
            "startOffset": 32232,
            "title": "Co-primary objectives"
        },
        {
            "endOffset": 28401,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "Unsolicited AEs were recorded for 30 days (D0\u2013D29) after each vaccination.",
            "startOffset": 28327,
            "title": "Assessment of reactogenicity and safety"
        },
        {
            "endOffset": 43318,
            "parents": [],
            "secId": "s0090",
            "sentence": "However, as PRN-specific immune responses in the Co-Ad group compared favorably to protective levels in a German household contact study, these data do not suggest a clinically relevant interference between RZV and Tdap.",
            "startOffset": 43098,
            "title": "Conclusions"
        },
        {
            "endOffset": 45045,
            "parents": [],
            "secId": "s0141",
            "sentence": "HL is currently an employee of Pfizer and receives salary and stock as part of his employee remuneration.",
            "startOffset": 44940,
            "title": "Declaration of Competing Interest"
        },
        {
            "endOffset": 23474,
            "parents": [],
            "secId": "s0005",
            "sentence": "Given that administration of vaccines at a single visit is more convenient and cost effective, and might improve vaccine coverage, this study evaluated the immunogenicity and safety when the first dose of RZV was co-administered with Tdap as compared to sequential administration.",
            "startOffset": 23194,
            "title": "Introduction"
        },
        {
            "endOffset": 43399,
            "parents": [],
            "secId": "s0090",
            "sentence": "Immunogenicity of RZV was not adversely impacted by co-administration with Tdap.",
            "startOffset": 43319,
            "title": "Conclusions"
        },
        {
            "endOffset": 29565,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "Suspected HZ, defined as appearance of a new rash characteristic of HZ and diagnosed by the investigator, were collected until study end.",
            "startOffset": 29428,
            "title": "Assessment of reactogenicity and safety"
        },
        {
            "endOffset": 43888,
            "parents": [],
            "secId": "s0095",
            "sentence": "GlaxoSmithKline Biologicals SA also took responsibility for all costs associated with the development and publishing of the present manuscript.",
            "startOffset": 43745,
            "title": "Funding"
        },
        {
            "endOffset": 32998,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0060",
            "sentence": "To demonstrate all co-primary objectives with a global power of 90%, a sample size of 778 evaluable participants (389 per study group) were needed.",
            "startOffset": 32851,
            "title": "Sample size calculation"
        },
        {
            "endOffset": 44839,
            "parents": [],
            "secId": "s0141",
            "sentence": "TCH and LO are inventors on a patent owned by the GSK group of companies and relevant to RZV.",
            "startOffset": 44746,
            "title": "Declaration of Competing Interest"
        },
        {
            "endOffset": 34846,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The non-inferiority criterion (UL of 95% CI <1.5) for the humoral immune response to Tdap in the Co-Ad compared to the Control group was met for the pertussis antigens except PRN.",
            "startOffset": 34667,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 33231,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "From 904 enrolled participants, 903 were randomized and received at least one study vaccine dose.",
            "startOffset": 33134,
            "title": "Study participants"
        },
        {
            "endOffset": 40239,
            "parents": [],
            "refoffsets": {
                "b0205": {
                    "endOffset": 40238,
                    "startOffset": 40234
                }
            },
            "secId": "s0085",
            "sentence": "The immune responses to these three pertussis antigens in the Co-Ad group compare favorably to the levels observed in the household contact study participants following a 3rd DTaP dose (Fig. 3) [41].",
            "startOffset": 40040,
            "title": "Discussion"
        },
        {
            "endOffset": 37455,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "The most frequently reported unsolicited AEs of any grade were injection site pruritus in the Co-Ad group (2.4% of participants), and injection site pruritus and viral upper respiratory tract infection in the Control group (1.9% of participants each).",
            "startOffset": 37204,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 31733,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Descriptive analyses of reactogenicity and safety were performed on the total vaccinated cohort (TVC) and included all participants with at least 1 documented administered vaccine dose, except those from a study center that was excluded from the analysis.",
            "startOffset": 31478,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 44011,
            "parents": [],
            "secId": "s0100",
            "sentence": "LC, IE, HL, NS and AS collected or generated study data.",
            "startOffset": 43955,
            "title": "Author\u2019s contributions"
        },
        {
            "endOffset": 28852,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "All solicited AEs were graded on a scale from 0 (characterized by a surface diameter <20 mm [for swelling and redness], oral temperature <37.5 \u00b0C [for fever] or absent [for all other solicited AEs]) to 3 (characterized by a surface diameter >100 mm [for redness and swelling], significant at rest and preventing normal everyday activities [for pain], oral temperature >39.0 \u00b0C [for fever] or preventing normal activity [for all other solicited AEs]).",
            "startOffset": 28402,
            "title": "Assessment of reactogenicity and safety"
        },
        {
            "endOffset": 35856,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Overall, the percentage of participants reporting solicited local or general symptoms was similar in the Co-Ad and Control groups (Table 4).",
            "startOffset": 35716,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 36228,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "After Tdap vaccination, pain was reported by 45.1% (2.0% grade 3) and 38.1% (0.7% grade 3) of participants in the Co-Ad and Control groups, respectively (Fig. 2B).",
            "startOffset": 36065,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 38110,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "This HZ episode was assessed by the investigator as not causally related to vaccination and it resolved in 8 days.",
            "startOffset": 37996,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 39381,
            "parents": [],
            "secId": "s0085",
            "sentence": "For both anti-D and anti-T concentrations, the non-inferiority criterion for co-administration was met.",
            "startOffset": 39278,
            "title": "Discussion"
        },
        {
            "endOffset": 28326,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0030",
                    "title": "Outcomes and assessments"
                }
            ],
            "secId": "s0040",
            "sentence": "Solicited local (injection site pain, redness and swelling) and general (fatigue, fever, gastrointestinal symptoms, headache, myalgia, and shivering) AEs were recorded for 7 days (D0\u2013D6) after each vaccination.",
            "startOffset": 28116,
            "title": "Assessment of reactogenicity and safety"
        },
        {
            "endOffset": 33105,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0060",
            "sentence": "Assuming 5% non-evaluable participants, 820 participants (410 per study group) were needed to be enrolled.",
            "startOffset": 32999,
            "title": "Sample size calculation"
        },
        {
            "endOffset": 23193,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 23192,
                    "startOffset": 23185
                },
                "b0150": {
                    "endOffset": 23192,
                    "startOffset": 23185
                }
            },
            "secId": "s0005",
            "sentence": "Recent trials indicate that the immunogenicity of RZV is preserved and that the reactogenicity of neither of the vaccines is significantly impacted when the first dose is co-administered with either a seasonal inactivated quadrivalent influenza vaccine (IIV4) or a 23-valent pneumococcal polysaccharide vaccine (PPSV23) [29,30].",
            "startOffset": 22865,
            "title": "Introduction"
        },
        {
            "endOffset": 42078,
            "parents": [],
            "secId": "s0085",
            "sentence": "The results of this study should be interpreted considering its limitations.",
            "startOffset": 42002,
            "title": "Discussion"
        },
        {
            "endOffset": 21113,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 21112,
                    "startOffset": 21107
                },
                "b0020": {
                    "endOffset": 21112,
                    "startOffset": 21107
                }
            },
            "secId": "s0005",
            "sentence": "Complications of HZ include postherpetic neuralgia, ophthalmic disease, myelitis, and encephalitis [1,4].",
            "startOffset": 21008,
            "title": "Introduction"
        }
    ],
    "docId": "S0264410X19310266",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "ana.x.strezova@gsk.com",
                "first": "Ana",
                "initial": "A.",
                "last": "Strezova"
            },
            {
                "email": "himallal@pfizer.com",
                "first": "Himal",
                "initial": "H.",
                "last": "Lal"
            },
            {
                "email": "igwebuike.x.enweonye@gsk.com",
                "first": "Igwebuike",
                "initial": "I.",
                "last": "Enweonye"
            },
            {
                "email": "laura.e.campora@gsk.com",
                "first": "Laura",
                "initial": "L.",
                "last": "Campora"
            },
            {
                "email": "pierre.x.beukelaers@gsk.com",
                "first": "Pierre",
                "initial": "P.",
                "last": "Beukelaers"
            },
            {
                "email": "nsegall@clinicalresearchatlanta.com",
                "first": "Nathan",
                "initial": "N.",
                "last": "Segall"
            },
            {
                "email": "tch3768@gmail.com",
                "first": "Thomas C.",
                "initial": "T.C.",
                "last": "Heineman"
            },
            {
                "email": "Anne.E.Schuind@gsk.com",
                "first": "Anne E.",
                "initial": "A.E.",
                "last": "Schuind"
            },
            {
                "email": "cornelia.oostvogels@orange.fr",
                "first": "Lidia",
                "initial": "L.",
                "last": "Oostvogels"
            }
        ],
        "doi": "10.1016/j.vaccine.2019.08.001",
        "firstpage": "5877",
        "issn": "0264410X",
        "keywords": [
            "Adjuvanted recombinant zoster vaccine",
            "Co-administration",
            "Herpes zoster",
            "Immune response",
            "Reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine",
            "Safety"
        ],
        "lastpage": "5885",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged \u226550 years: A randomized trial"
    }
}